Attorney Docket No.: 57070-8021.US00

PATENTS

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

YUAN et al.

EXAMINER: CHANDRAKUMAR, N.

APPLICATION No.: 10/591,358

ART UNIT: 1625 CONF. NO: 9546

FILED: August 12, 2008

FOR: TRIPTOLIDE LACTONE RING DERIVATIVES AS IMMODULATORS AND ANTICANCER

AGENTS

## REVOCATION AND GRANT OF POWER OF ATTORNEY, CHANGE OF CORRESPONDENCE ADDRESS, AND STATEMENT UNDER 37 CFR 3.73(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

# Revocation/Grant of Power of Attorney

PHARMAGENESIS, INC., the owner by assignment of all right, title, and interest in and to the subject application, hereby revokes all powers of attorney heretofore granted for the above-identified application and hereby appoints the practitioners associated with <a href="Customer Number 79975">Customer Number 79975</a> as the attorneys of record herein, with full power of substitution and revocation, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

### Change of Correspondence Address

Please direct all future correspondence in the application to King & Spalding, at the address associated with the customer number provided above.

### Statement Under 37 CFR 3.73(b)

Assignee, PHARMAGENESIS, INC., having a place of business at 303 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065 certifies that it is assignee of the entire right, title, and interest in the above-identified patent application by virtue of a chain of title from the respective inventors of the subject matter disclosed and claimed therein. The chain of title is as set forth below:

 An assignment of the application from inventors, Hongwei Yuan, John H. Musser and Dongcheng Dai, to PHARMAGENESIS, INC. The assignment was recorded in the United States Patent and Trademark Office on November 14, 2008, at Reel 021839, Frame 0294.

The undersigned is empowered to sign this Revocation and Grant of Power of Attorney on behalf of the Assignee.

PHARMAGENESIS, INC.

Ti+I

Date: MA/18, 2010